Table 2.
Median (Q1–Q3) serum minerals, actual bicarbonate and intact parathyroid hormone parameters of the two study groups (PPS) at baseline, Weeks 9 and 25 (for the statistical analyses between treatment groups, values were adjusted for the baseline value, centre and covariates)
| Laboratory parameter | CaMg |
Sevelamer-HCl |
Significance (between groups) ANCOVA (repeated measures) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 9 | Wilcoxon test (W1 versus W9) | Week 25 | Wilcoxon test (W9 versus W25) | Week 1 | Week 9 | Wilcoxon test (W1 versus W9) | Week 25 | Wilcoxon test (W9 versus W25) | ||
| Phosphorus (mmol/L) | 2.41; 2.05–2.73 | 1.65; 1.35–2.04 | P < 0.0001 | 1.66; 1.30–1.98 | P = 0.4802 | 2.42; 2.12–2.78 | 1.78; 1.45–2.10 | P < 0.0001 | 1.69; 1.32–2.02 | P = 0.7013 | P = 0.1635 |
| Total calcium (mmol/L) | 2.20; 2.03–2.30 | 2.22; 2.13–2.36 | P = 0.0001 | 2.24; 2.14–2.34 | P = 0.8032 | 2.17; 2.09–2.31 | 2.22; 2.11–2.31 | P = 0.3285 | 2.20; 2.06–2.30 | P = 0.0565 | P = 0.0053 |
| Ionized calcium (mmol/L) | 1.09; 1.01–1.16 | 1.13; 1.08–1.18 | P < 0.0001 | 1.13; 1.07–1.19 | P = 0.9442 | 1.09; 1.03–1.16 | 1.13; 1.09–1.19 | P < 0.0001 | 1.13; 1.07–1.18 | P = 0.0588 | P = 0.7356 |
| Magnesium (mmol/L) | 0.98; 0.89–1.09 | 1.26; 1.15–1.41 | P < 0.0001 | 1.28; 1.15–1.46 | P = 0.2868 | 0.99; 0.89–1.09 | 1.07; 0.96–1.17 | P < 0.0001 | 1.04; 0.95–1.15 | P = 0.0537 | P < 0.0001 |
| Actual bicarbonate (mmol/L) | 21.3; 19.1–23.2 | 23.3; 21.2–25.3 | P < 0.0001 | 23.0; 20.3–25.2 | P = 0.8501 | 20.9; 18.8–22.9 | 20.2; 18.1–22.9 | P = 0.0442 | 20.2; 17.8–23.6 | P = 0.4566 | P = 0.0002 |
| iPTH (pg/mL) | 390; 251–607 | 283; 187–478 | P < 0.0001 | 312; 159–436 | P = 0.1159 | 422; 286–557 | 345; 217–468 | P < 0.0001 | 373; 227–521 | P = 0.0896 | P = 0.0553 |
ANCOVA, analysis of covariance; CaMg; calcium acetate/magnesium carbonate; HCI, hydrochloride; iPTH, intact parathyroid hormone; PPS, per protocol set.